New study explores work challenges for men with cancer
NCT ID NCT05250284
First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This study looks at how cancer treatment impacts the work life and overall well-being of 400 men, ages 21 to 70, who have been newly diagnosed with solid tumors like colorectal, lung, or head and neck cancer. Participants will fill out questionnaires about their work hours, financial stress, and emotional health over 12 months. The goal is to better understand the challenges low-income and Latino men face while balancing treatment and employment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors and employers better support cancer patients who want to keep working during treatment.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2022
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
sample consists of employed men newly diagnosed with a first primary solid tumor. define employed as working 10+ hours per week at diagnosis with the intention to continue working or return to work. Patients must be aged 21 to 70 years and within 2 months of initiating infusion chemotherapy, oral agent, or radiation therapy.
- Ages
-
21 to 70 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males * Ages 21 to 70 * Newly diagnosed with a first primary solid tumor * colorectal, lung, and head and neck * Currently employed (defined as working 10+ hours per week) with the intention to continue working or return to work * Within 2 months of initiating infusion chemotherapy, oral agent, or radiation therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a dental assistant keep cancer Patients' mouths healthier during radiation?
- Gut bacteria may hold clues to why some cancer treatments work better
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors